This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 Resilient Dental Supply Players Positioned to Withstand Tariff Risks
by Indrajit Bandyopadhyay
Here, we discuss four stocks from the Dental Supplies industry that are likely to generate wealth for investors amid tariff uncertainty. These are MCK, CAH, WST and COO.
Ahead of McKesson (MCK) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top-and-bottom-line estimates for McKesson (MCK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2025.
Earnings Preview: Dentsply International (XRAY) Q3 Earnings Expected to Decline
by Zacks Equity Research
Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardinal Health (CAH) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of +15.38% and +8.39%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
McKesson (MCK) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
McKesson (MCK) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
McKesson (MCK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Baxter Q3 Preview: Can Core Segments Deliver Another Solid Quarter?
by Zacks Equity Research
Baxter's Q3 results are expected to show steady revenue growth led by Advanced Surgery and Drug Compounding, though IV fluid and anesthesia softness may weigh on EPS.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
McKesson (MCK) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
McKesson (MCK) reached $801.67 at the closing of the latest trading day, reflecting a +1.1% change compared to its last close.
Will SYK's Q3 Results Reflect MedSurg Strength & Rebound in Orthopaedics?
by Zacks Equity Research
Stryker's Q3 results are expected to highlight MedSurg strength and solid robotics-led growth in Orthopaedics, partly offset by tariff headwinds.
Pharma, Specialty Units Likely to Drive Cardinal Health's Q1 Earnings
by Zacks Equity Research
CAH's Pharmaceutical and Specialty units are expected to have fueled double-digit revenue growth in Q1 FY26 despite tariff and cost headwinds.
McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Will RVTY Q3 Earnings Reflect Segmental Strength Amid Rising Demand?
by Zacks Equity Research
RVTY's third-quarter results are likely to reflect strong performance in the Life Sciences segment. However, the Diagnostic segment is set to face challenges in China.
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
McKesson (MCK) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
McKesson (MCK) reached $786 at the closing of the latest trading day, reflecting a +1.36% change compared to its last close.
WST Q3 Earnings Preview: Can GLP-1 Momentum Outweigh Margin Pressure?
by Zacks Equity Research
West Pharma's Q3 numbers hinge on robust GLP-1 and biologics demand, but labor constraints, tariffs, and plant shutdowns could test its margin resilience.
The Zacks Analyst Blog Highlights UBS, Newmont, McKesson and The Cato
by Zacks Equity Research
Zacks spotlights UBS, Newmont, McKesson, and Cato, four companies showing strong performance across finance, gold mining, healthcare distribution, and retail.
Top Research Reports for UBS, Newmont & McKesson
by Mark Vickery
UBS advances on solid earnings and integration progress, while Newmont and McKesson deliver strong gains through expansion and operational efficiency.
Why McKesson (MCK) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
McKesson (MCK) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, McKesson (MCK) stood at $781.9, denoting a +1.61% move from the preceding trading day.
Here's Why McKesson (MCK) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
If You Invested $1000 in McKesson a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Investors Heavily Search McKesson Corporation (MCK): Here is What You Need to Know
by Zacks Equity Research
McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
McKesson Bets on Oncology, Biopharma as It Streamlines Portfolio
by Zacks Equity Research
MCK is transforming from a traditional distributor into a specialty-driven healthcare solutions leader, focusing on oncology, biopharma services and automation while preparing to separate its Medical-Surgical unit.